Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Impact · against what's priced in

Celldex sees a potential valuation lift as new Phase 2 data suggests barzolvolimab may act as a disease-modifying therapy rather than just symptom control, with 64% of patients remaining angioedema-free seven months post-treatment. This evidence of sustained off-treatment benefit increases the drug's competitive profile ahead of the Phase 3 readouts expected in Q4 2026.

CLDX+0.60

No priced-in read yet